FOR IMMEDIATE RELEASE

Lewisville, TX – July 9, 2007 - Genesis Biosystems Inc., announced today the official launch of Regenlite™ for sale in the United States, the latest generation pulsed dye laser offering non-ablative skin treatment procedures for use in the aesthetics industry. Regenlite™ is the product of 10 years of research and clinical experience in over 500 aesthetic practices worldwide.

The Regenlite™ provides the operator with two modes of operation, the rejuvenation mode and the vascular mode. In the rejuvenation mode the Regenlite provides remarkable results for all grades of Acne Vulgaris, including cystic acne; performs dermal remodeling and skin tightening; reduces lines and wrinkles; improves irregular pigmentation and stimulates collagen for the treatment of acne scars, traumatic and surgical scarring.

In the vascular mode, the Regenlite™ treats Port Wine Stains, Rosacea, Telangiectasias, Angiomas, Psoriasis and also removes warts and veruccas. All of these indications are performed quickly with no patient discomfort.

Regenlite™ is proven by science. Research at the University Hospital of Aarhus, Denmark, demonstrated that a single Regenlite treatment increased overall collagen production by 148% after a second laser session was performed 14 days later. Equally amazing results were published in the Lancet and British Journal of Dermatology regarding treatments of acne lesions and acne scarring.

The offering company Genesis Biosystems Inc. was founded by two biomedical engineers and a leading plastic and reconstructive surgeon from Stanford University and is an ISO 13485 certified quality manufacturer operating in an FDA registered facility in Dallas, Texas.